CASP3 and central nervous system cancer: Interestingly, treatment with compound 1 led to significant caspase 3/7 activation in lymphoma (Z-138, Jeko-1, Granta and SP-53) but not in leukemia (JURKAT) or glioma (LN229 and U87MG) cell lines.